A multisocietal consensus has endorsed cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating diffuse malignant peritoneal mesothelioma (DMPM). An expert panel, acknowledging the limited efficacy of systemic chemotherapy, strongly recommended this approach for a select subgroup of patients. Despite low evidence certainty, the panel emphasized the potential for improved survival outcomes with CRS-HIPEC, advocating for broader acceptance and centralized care for this rare and aggressive cancer.
Journal Article by Kusamura S, Cinquini M (…) Marcello D et 11 al. in J Surg Oncol
© 2024 Wiley Periodicals LLC.